Clinical trials: Hospitalized COVID-19
COVID-19
Study to Evaluate the Efficacy and Safety of Remdesivir in Participants With Severely Reduced Kidney Function Who Are Hospitalized for Coronavirus Disease 2019 (COVID-19)
The primary objective of this study is to evaluate whether remdesivir (RDV, GS-5734™) reduces the composite risk of death or invasive mechanical ventilation (IMV) through Day 29 in participants with severely reduced kidney…
- Trial name
- REDPINE (NCT04745351)
- Testing
- Remdesivir, Standard of Care
- Where
- 63 sites in United States, Brazil and 4 more
- Volunteers
- 249 people
- Sponsor
- Gilead Sciences
Critical Illness
Modified Pediatric Early Warning Score and Modified PRISA II During COVID-19 Pandemic
One of the most important factors in pediatric emergency units is the correct decision of the patient inpatient or outpatient treatment. If the disease progresses critically, the decision of hospitalization comes to the fore.
- Trial name
- NCT04876872
- Testing
- no intervention
- Where
- Turkey (Türkiye)
- Volunteers
- 894 people
- Sponsor
- Karadeniz Technical University
COVID-19
Validation of Prognostic Clinical Risk Scores in Predicting Outcome for Patients With COVID-19 at Initial Triage
Background Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) causing Covid-19 pandemic continues to be a global health threat with a massive burden on health care systems resulting in more than six million deaths in…
- Trial name
- NCT05582382
- Testing
- logistic regression of known prognostic markers of severity of COVID19
- Where
- United Arab Emirates
- Volunteers
- 2,000 people
- Sponsor
- Dr Adnan Agha
Covid-19
Changes in Cardiac and Pulmonary Hemodynamics as Predictor of Outcome in Hospitalized COVID-19 Patients
The primary objective of the study is to evaluate cardiac and pulmonary hemodynamic changes over time as predictor of disease progression and outcome in COVID-19 patients admitted to ICU.
- Trial name
- COVID-HO (NCT04371679)
- Testing
- No interventions planned
- Where
- Belgium
- Volunteers
- 40 people
- Sponsor
- Hasselt University
Covid19, Corona Virus Infection
A Study of Baricitinib (LY3009104) in Children With COVID-19
The purpose for this study is to determine if the study drug baricitinib is effective and safe in hospitalized pediatric participants with Coronavirus disease 2019 (COVID -19) and to confirm the dose.
- Trial name
- COV-BARRIER (NCT05074420)
- Testing
- Baricitinib
- Where
- 14 sites in United States, Brazil and 2 more
- Volunteers
- 6 people
- Sponsor
- Eli Lilly and Company
SARS-CoV-2 Infection
Pulmonary Function in Non-hospitalized Adults and Children After Mild COVID-19
The study investigates whether patients with mild SARS-CoV-2 infection, who stayed at home during their infection and weren't hospitalized, have any persisting sequelae in pulmonary function.
- Trial name
- NCT06318208
- Testing
- lung function testing
- Where
- Germany
- Volunteers
- 110 people
- Sponsor
- University of Rostock
COVID 19
Eccentric Cycling Vs. Standard Rehabilitation for Post-ICU Recovery in COVID-19 Survivors
We performed a longitudinal crossover clinical study on survivors of COVID-19. We compared a standard rehabilitation protocol using elastic bands versus a novel eccentric cycling training protocol in individuals who have been…
- Trial name
- ECC-4-COVID (NCT06895850)
- Testing
- Eccentric cycling training, Standar Rehabilitation
- Where
- Chile
- Volunteers
- 20 people
- Sponsor
- Universidad Nacional Andres Bello
COVID-19 Pneumonia
A Study to Evaluate the Efficacy and Safety of Remdesivir Plus Tocilizumab Compared With Remdesivir Plus Placebo in Hospitalized Participants With Severe COVID-19 Pneumonia
This study will evaluate the efficacy and safety of combination therapy with remdesivir plus tocilizumab compared with remdesivir plus placebo in hospitalized patients with COVID-19 pneumonia.
- Trial name
- REMDACTA (NCT04409262)
- Testing
- Remdesivir, Tocilizumab
- Where
- 54 sites in United States, Brazil and 2 more
- Volunteers
- 649 people
- Sponsor
- Hoffmann-La Roche
COVID-19
The Evaluation of Hemostasis in Hospitalized COVID-19 Patients
Coronavirus disease 2019 (COVID-19), a viral respiratory illness caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has been shown to predispose patients to thrombotic diseases (venous and arterial) with…
- Trial name
- TARGET-COVID (NCT04493307)
- Testing
- Phlebotomy
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- LifeBridge Health
COVID-19
A Real World Study of Paxlovid for the Treatment of Hospitalized Patients Confirmed With COVID-19
The study was designed to analyze the efficacy and safety of Paxlovid for the treatment of COVID-19.
- Trial name
- NCT05387369
- Testing
- Paxlovid
- Where
- China
- Volunteers
- 2,000 people
- Sponsor
- Huashan Hospital
Acute Kidney Injury, Covid19
Renal Involvement in Hospitalized Children With COVID-19
Covid-19 is an important human and animal pathogen, it mostly causes respiratory and gastrointestinal symptoms. Clinical features range from a common cold to severe diseases such as severe acute respiratory distress syndrome…
- Conditions
- Acute Kidney Injury, Covid19, Renal Dysfunction, Coronavirus Infection
- Trial name
- RIHCC (NCT04788394)
- Testing
- data review, data comparing
- Where
- Qatar
- Volunteers
- 400 people
- Sponsor
- Hamad Medical Corporation
Asymptomatic COVID-19
Study of Oral High/Low-dose Cepharanthine Compared With Placebo in Non Hospitalized Adults With COVID-19
The purpose of this study is to evaluate the efficacy and safety of high/low-dose cepharanthine for the Treatment of COVID-19 in asymptomatic and non-pneumonia mild adult participants with COVID-19 who do not need to be in the…
- Trial name
- NCT05398705
- Testing
- Cepharanthine
- Where
- 2 sites in China
- Volunteers
- 450 people
- Sponsor
- Shanghai Jiao Tong University School of Medicine
COVID-19
EPIC-Peds: A Study to Learn About the Study Medicine Called PF-07321332 (Nirmatrelvir)/Ritonavir in Patients Under 18 Years of Age With COVID-19 That Are Not Hospitalized But Are at Risk for Severe Disease
The purpose of this clinical trial is to learn about the safety, pharmacokinetics (pharmacokinetics helps us understand how the drug is changed and eliminated from your body after you take it), and efficacy (how well a study…
- Trial name
- NCT05261139
- Testing
- nirmatrelvir, ritonavir
- Where
- 73 sites in United States, Bulgaria and 5 more
- Volunteers
- 160 people
- Sponsor
- Pfizer
Psychiatric Disorder, Covid19
PSYCHIATRIC Disorders and Covid-19
Given the possible risks and complications of a comorbidity between psychiatric disorder and coronavirus disease 2019 (COVID-19), it seems particularly important to specify the impact of the COVID-19 pandemic in patients with…
- Trial name
- PSYCHIC (NCT04358042)
- Testing
- Brief Psychiatric Rating Scale, Depression, Anxiety and Stress Scale, Impact of Event Scale-Revised
- Where
- France
- Volunteers
- 20 people
- Sponsor
- Nantes University Hospital
Hyponatremia, Covid19
HYPONATREMIA IN COVID-19 PATIENTS
SYSTEMIC INFLAMMATION HAS BEEN ASSOCIATED WITH SEVERE COVID-19. HYPONATREMIA CAN RESULT FROM INFLAMMATION DUE TO NON-OSMOTIC STIMULI FOR VASOPRESSIN PRODUCTION.
- Conditions
- Hyponatremia, Covid19, Corona Virus Infection
- Trial name
- NCT04493268
- Where
- Argentina
- Volunteers
- 250 people
- Sponsor
- Hospital Nacional Profesor Alejandro Posadas
Coronavirus Infections, Diabetes Mellitus
Covid-19 and Diabetes in West of Algeria
By Jan 7, 2020, Chinese scientists had isolated a novel coronavirus, from patients with virus-infected pneumonia. The WHO designated later this virus as COVID-19 (coronavirus disease 2019).
- Conditions
- Coronavirus Infections, Diabetes Mellitus, Prevalence, Risk Factors
- Trial name
- COVIDIAB-13 (NCT04412746)
- Testing
- MANAGEMENT OF COVID-19
- Where
- Algeria
- Volunteers
- 100 people
- Sponsor
- Laboratoire De Recherche Sur Le Diabete, Université de Tlemcen
Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), Coronavirus Disease 2019 (COVID-19)
A Study to Learn About the Medicine Called Nirmatrelvir Used in Combination With Ritonavir in People With Weakened Immune Systems or at Increased Risk for Poor Outcomes Who Are Hospitalized Due to Severe COVID-19
A Study to Learn About the Medicine Called Nirmatrelvir Used in Combination With Ritonavir in People with Weakened Immune Systems or at Increased Risk for Poor Outcomes who are Hospitalized Due to Severe COVID-19
- Conditions
- Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), Coronavirus Disease 2019 (COVID-19), Immunocompromised, Hospitalization
- Trial name
- EPIC-HOS (NCT05545319)
- Testing
- Nirmatrelvir, Ritonavir
- Where
- 11 sites in United States, Bulgaria
- Sponsor
- Pfizer
COVID-19
CORONA Germany- Clinical Outcome and Risk in Hospitalized COVID-19 Patients - An Epidemiological Study From Germany
This is a multicenter, observational, prospective, epidemiological cohort study at 45 hospitals in Germany, all part of a German hospital network. All hospitalized patients tested positive for SARS-CoV-2 will be included.
- Trial name
- CORONA Germany (NCT04659187)
- Where
- 8 sites in Germany
- Volunteers
- 4,000 people
- Sponsor
- Asklepios proresearch
COVID-19 Pandemic, Children, Only
Quality of Nursing Care During The Covid-19 Pandemic
Enabling school-age children to evaluate the care they receive provides feedback on the quality of care by determining children's satisfaction with care, and gives important feedback on the quantity and quality of care.
- Conditions
- COVID-19 Pandemic, Children, Only, Hospitalism, Nurse's Role
- Trial name
- NCT05841602
- Testing
- descriptive
- Where
- Turkey (Türkiye)
- Volunteers
- 128 people, healthy volunteers welcome
- Sponsor
- Tokat Gaziosmanpasa University
Coronavirus Disease 2019
Clinical Outcomes of Patients With COVID19
As of February 17th, 2020, China has 70635 confirmed cases of coronavirus disease 2019 (COVID-19), including 1772 deaths. Human-to-human spread of virus via respiratory droplets is currently considered to be the main route of…
- Trial name
- NCT04280913
- Testing
- retrospective analysis
- Where
- China
- Sponsor
- Guangzhou Institute of Respiratory Disease